Context Therapeutics (CNTX) Income towards Parent Company (2020 - 2026)

Context Therapeutics has reported Income towards Parent Company for 7 years, with the latest figure at -$18.3 million in Q1 2026.

• Quarterly Income towards Parent Company fell 300.22% year-over-year to -$18.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.7 million (up 3.96% YoY) and the FY2025 annual result came in at -$72.2 million, down 40.29% from the prior year.
• Income towards Parent Company slipped to -$18.3 million in Q1 2026 per CNTX's latest filing, from -$16.1 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$3.4 million in Q1 2022 and troughed at -$28.1 million in Q4 2024.
• A 5-year average of -$10.7 million and a median of -$6.8 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company plunged 319.73% in 2022, then soared 45.29% in 2025.
• Over 5 years, Income towards Parent Company stood at -$13.1 million in 2022, then tumbled by 80.04% to -$23.5 million in 2023, then retreated by 19.4% to -$28.1 million in 2024, then soared by 42.85% to -$16.1 million in 2025, then decreased by 13.87% to -$18.3 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$18.3 million, -$16.1 million, and -$10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.